Geode Capital Management LLC Boosts Stake in GeneDx Holdings Corp. $WGS

Geode Capital Management LLC increased its position in GeneDx Holdings Corp. (NASDAQ:WGS) by 3.1% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 504,567 shares of the company’s stock after buying an additional 15,170 shares during the period. Geode Capital Management LLC owned 1.75% of GeneDx worth $65,635,000 at the end of the most recent quarter.

A number of other hedge funds also recently made changes to their positions in the company. Williamson Legacy Group LLC purchased a new stake in shares of GeneDx in the fourth quarter worth about $1,241,000. Legato Capital Management LLC lifted its position in shares of GeneDx by 4.5% in the fourth quarter. Legato Capital Management LLC now owns 10,240 shares of the company’s stock worth $1,332,000 after buying an additional 440 shares in the last quarter. PNC Financial Services Group Inc. lifted its position in shares of GeneDx by 33.4% in the fourth quarter. PNC Financial Services Group Inc. now owns 4,092 shares of the company’s stock worth $532,000 after buying an additional 1,025 shares in the last quarter. Csenge Advisory Group purchased a new stake in shares of GeneDx in the fourth quarter worth about $534,000. Finally, ProShare Advisors LLC lifted its position in shares of GeneDx by 8.0% in the fourth quarter. ProShare Advisors LLC now owns 3,467 shares of the company’s stock worth $451,000 after buying an additional 257 shares in the last quarter. 61.72% of the stock is currently owned by hedge funds and other institutional investors.

GeneDx Trading Down 0.8%

Shares of WGS stock opened at $51.80 on Tuesday. GeneDx Holdings Corp. has a 1 year low of $32.21 and a 1 year high of $170.87. The company has a debt-to-equity ratio of 0.38, a current ratio of 3.09 and a quick ratio of 2.95. The stock’s 50 day simple moving average is $55.25 and its two-hundred day simple moving average is $92.12. The company has a market cap of $1.54 billion, a PE ratio of -19.33 and a beta of 1.96.

GeneDx (NASDAQ:WGS) last issued its quarterly earnings results on Monday, May 4th. The company reported ($0.28) earnings per share for the quarter, missing the consensus estimate of ($0.06) by ($0.22). GeneDx had a positive return on equity of 9.15% and a negative net margin of 17.58%.The business had revenue of $102.25 million during the quarter, compared to analysts’ expectations of $112.46 million. During the same quarter in the previous year, the company posted ($0.23) earnings per share. Research analysts predict that GeneDx Holdings Corp. will post -1 earnings per share for the current year.

Trending Headlines about GeneDx

Here are the key news stories impacting GeneDx this week:

• Positive Sentiment: Director Casdin Capital bought 150,000 shares at an average price of $56.44, a sizable insider purchase that may signal management/board confidence in GeneDx’s long-term outlook. SEC filing
• Positive Sentiment: Casdin Capital also reported another purchase of 50,000 shares at $52.86, reinforcing the recent insider accumulation trend. SEC filing
• Neutral Sentiment: Analyst coverage remains constructive overall, with GeneDx receiving an average rating of “Moderate Buy,” which may help support the stock over time. Analyst rating update
• Negative Sentiment: Multiple law firms announced or reminded investors about a securities class-action lawsuit against GeneDx, increasing legal overhang and uncertainty for shareholders. Class action announcement
• Negative Sentiment: The litigation centers on alleged investor harm tied to GeneDx’s prior disclosures and a sharp post-earnings selloff, keeping attention on operational and disclosure risks. Litigation article

Insider Activity at GeneDx

In other GeneDx news, Director Keith A. Meister purchased 46,273 shares of GeneDx stock in a transaction dated Friday, May 15th. The shares were purchased at an average cost of $38.91 per share, for a total transaction of $1,800,482.43. Following the completion of the acquisition, the director owned 4,784,570 shares in the company, valued at $186,167,618.70. This represents a 0.98% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director Casdin Capital, Llc purchased 50,000 shares of GeneDx stock in a transaction dated Friday, June 5th. The stock was acquired at an average price of $52.86 per share, for a total transaction of $2,643,000.00. Following the completion of the acquisition, the director owned 3,707,164 shares of the company’s stock, valued at approximately $195,960,689.04. This trade represents a 1.37% increase in their position. The SEC filing for this purchase provides additional information. Over the last quarter, insiders bought 2,256,420 shares of company stock worth $93,144,340 and sold 72,382 shares worth $4,889,473. Corporate insiders own 29.60% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts have issued reports on the company. Piper Sandler restated an “overweight” rating and set a $130.00 price objective (down from $160.00) on shares of GeneDx in a research report on Tuesday, February 24th. Jefferies Financial Group set a $150.00 price objective on GeneDx in a research report on Monday, February 23rd. Wells Fargo & Company restated an “overweight” rating and set a $75.00 price objective (down from $155.00) on shares of GeneDx in a research report on Tuesday, May 5th. Weiss Ratings downgraded GeneDx from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Monday, June 1st. Finally, Craig Hallum restated a “buy” rating and set a $85.00 price objective on shares of GeneDx in a research report on Tuesday, May 5th. Six equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $96.43.

GeneDx Profile

GeneDx is a clinical diagnostics company specializing in comprehensive genetic and genomic testing for rare and inherited disorders. The company offers a broad portfolio of assays, including targeted gene panels, whole exome sequencing, whole genome sequencing and chromosomal microarray analysis. GeneDx’s laboratory services support the diagnosis of a wide range of conditions—from rare pediatric diseases and hereditary cancer syndromes to neuromuscular and metabolic disorders—by providing clinicians with detailed variant interpretation and reporting.

Founded in 2000 and based in Gaithersburg, Maryland, GeneDx was established with the aim of accelerating the translation of genomic discoveries into clinical care.